Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

June 18, 2014 15:00 ET

Trimel to Present at the JMP Securities Healthcare Conference

TORONTO, ONTARIO--(Marketwired - June 18, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) today announced that management is scheduled to present an overview of the Company at the JMP Securities Healthcare Conference at the Westin New York Grand Central, New York on June 24, 2014 at 12:00 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.

For further information regarding Trimel Pharmaceuticals Corporation, please contact Kenneth Howling, Chief Financial Officer at (416) 679-0536 or Trimel via email at ir@trimelpharmaceuticals.com.

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto™, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com∩╗┐.

Contact Information